A. Asemissen

发表

E. Thiel, C. Scheibenbogen, U. Keilholz, 2005 .

Peptide vaccination after repeated resection of metastases can induce a prolonged relapse‐free interval in melanoma patients

E. Thiel, C. Scheibenbogen, U. Keilholz, 2005, International journal of cancer.

Rational peptide-based tumour vaccine development and T cell monitoring.

E. Thiel, C. Scheibenbogen, U. Keilholz, 2003, Seminars in cancer biology.

Addition of histamine to interleukin 2 treatment augments type 1 T-cell responses in patients with melanoma in vivo: immunologic results from a randomized clinical trial of interleukin 2 with or without histamine (MP 104).

E. Thiel, C. Scheibenbogen, K. Hellstrand, 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

Circulating Tumor-reactive CD8(+) T cells in melanoma patients contain a CD45RA(+)CCR7(-) effector subset exerting ex vivo tumor-specific cytolytic activity.

D. Schadendorf, E. Thiel, P. Romero, 2002, Cancer research.

Vaccination strategies in patients with renal cell carcinoma

P. Brossart, A. Asemissen, 2009, Cancer Immunology, Immunotherapy.

A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS.

E. Thiel, W. Hofmann, C. Scheibenbogen, 2009, Blood.

Flow cytometric determination of intracellular or secreted IFNgamma for the quantification of antigen reactive T cells.

E. Thiel, C. Scheibenbogen, U. Keilholz, 2001, Journal of immunological methods.

T‐cell diversification reflects antigen selection in the blood of patients on immune checkpoint inhibition and may be exploited as liquid biopsy biomarker

A. Krohn-Grimberghe, C. Bokemeyer, N. Akyüz, 2017, International journal of cancer.

Addition of GM-CSF to a peptide/KLH vaccine results in increased frequencies of CXCR3-expressing KLH-specific T cells

E. Thiel, C. Scheibenbogen, U. Keilholz, 2007, Cancer Immunology, Immunotherapy.

CMV‐specific central memory T cells reside in bone marrow

E. Thiel, H. Volk, C. Scheibenbogen, 2007, European journal of immunology.

Specific Central Memory T Cells in the Bone Marrow of Patients Immunized Against Tyrosinase Peptides

E. Thiel, F. Kern, C. Scheibenbogen, 2006, Journal of immunotherapy.

Cross-presentation of HLA class I epitopes from influenza matrix protein produced in Saccharomyces cerevisiae.

A. Meyerhans, C. Scheibenbogen, F. Neumann, 2006, Vaccine.

Malignant melanoma--clinical development of peptide-based melanoma vaccines.

E. Thiel, C. Scheibenbogen, U. Keilholz, 2006, Frontiers of radiation therapy and oncology.

Deep sequencing of bone marrow microenvironments of patients with del(5q) myelodysplastic syndrome reveals imprints of antigenic selection as well as generation of novel T-cell clusters as a response pattern to lenalidomide

D. Nowak, W. Hofmann, N. Akyüz, 2019, Haematologica.

Surgical Site Cytology to Diagnose Spinal Lesions

C. Bokemeyer, M. Dreimann, A. Asemissen, 2022, Diagnostics.

Lymphomas are sensitive to perforin-dependent cytotoxic pathways despite expression of PI-9 and overexpression of bcl-2.

E. Thiel, C. Scheibenbogen, U. Keilholz, 2006, Blood.

Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial

H. Goldschmidt, A. Jauch, Y. Ko, 2021, Leukemia.

Functional CCR9 expression is associated with small intestinal metastasis.

D. Schadendorf, E. Thiel, C. Scheibenbogen, 2004, The Journal of investigative dermatology.

CD56dimCD16neg cells are responsible for natural cytotoxicity against tumor targets

E. Thiel, C. Scheibenbogen, C. Gentilini, 2005, Leukemia.

WT1-Peptide Vaccination Shows High Immunogenicity and Clinical Activity in Patients with Acute Myeloid Leukemia.

W. Hofmann, C. Scheibenbogen, A. Letsch, 2005 .

Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial.

H. Goldschmidt, E. Nievergall, T. Holderried, 2022, The Lancet. Haematology.

WT1) peptide vaccination in patients with AML and MDS A clinical and immunologic phase 2 trial of Wilms tumor gene product 1

E. Thiel, W. Hofmann, C. Scheibenbogen, 2009 .

Isatuximab, Carfilzomib, Lenalidomide and Dexamethasone (I-KRd) in front-line treatment of high-risk Multiple Myeloma: Results of the Safety Run-In cohort in the phase II, multicenter GMMG-CONCEPT trial

H. Goldschmidt, C. Bokemeyer, A. Benner, 2019, Clinical Lymphoma Myeloma and Leukemia.

Systemic Immune Tuning in Renal Cell Carcinoma: Favorable Prognostic Impact of TGF-&bgr;1 mRNA Expression in Peripheral Blood Mononuclear Cells

E. Thiel, K. Miller, U. Keilholz, 2011, Journal of immunotherapy.

Quantitative DNA methylation analysis of FOXP3 as a new method for counting regulatory T cells in peripheral blood and solid tissue.

Fabian Model, Sven Olek, Ulrich Hoffmüller, 2009, Cancer research.

Addition of Isatuximab to Lenalidomide, Bortezomib and Dexamethasone As Induction Therapy for Newly-Diagnosed, Transplant-Eligible Multiple Myeloma Patients: The Phase III GMMG-HD7 Trial

H. Goldschmidt, E. Nievergall, T. Holderried, 2021, Blood.

Immunomodulatory effects of sorafenib on peripheral immune effector cells in metastatic renal cell carcinoma.

E. Thiel, K. Miller, U. Keilholz, 2011, European journal of cancer.

Identification of an Immunogenic HLA-A*0201-binding T-cell Epitope of the Transcription Factor PAX2

E. Thiel, H. Rammensee, S. Stevanović, 2009, Journal of immunotherapy.

Identification of a Highly Immunogenic HLA-A*01-Binding T Cell Epitope of WT1

E. Thiel, H. Rammensee, S. Stevanović, 2006, Clinical Cancer Research.

Identification of known and novel immunogenic T‐cell epitopes from tumor antigens recognized by peripheral blood T cells from patients responding to IL‐2‐based treatment

D. Schadendorf, E. Thiel, H. Rammensee, 2002, International journal of cancer.

Comparison of bone marrow and peripheral blood aberrant plasma cell assessment by NGF in patients with MM

H. Goldschmidt, J. Dürig, C. Müller-Tidow, 2022, Blood Advances.

Depth of Response to Isatuximab, Carfilzomib, Lenalidomide and Dexamethasone (Isa-KRd) in Front-Line Treatment of High-Risk Multiple Myeloma: Interim Analysis of the GMMG-CONCEPT Trial

H. Goldschmidt, A. Jauch, Y. Ko, 2021, SSRN Electronic Journal.

Fulminant blast crisis with de novo 11q23 rearrangement in a Philadelphia-positive CML patient undergoing treatment with dasatinib

C. Bokemeyer, J. Dierlamm, M. Binder, 2019, Tumori.

Sunitinib Treatment for Patients with Advanced Clear-Cell Renal-Cell Carcinoma after Progression on Sorafenib

E. Thiel, U. Steiner, K. Miller, 2009, Oncology.

Induction of multidrug resistance on mRNA and on protein level by fractionated irradiation

T. Wiegel, D. Bottke, W. Hinkelbein, 2004 .

Identification of a Highly Immunogenic HLA-A*01-Binding T Cell Epitope of WT1

E. Thiel, H. Rammensee, S. Stevanović, 2006, Clinical Cancer Research.

P930: ISATUXIMAB, LENALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE AS INDUCTION THERAPY FOR NEWLY-DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH HIGH-RISK CYTOGENETICS: A SUBGROUP ANALYSIS FROM THE GMMG-HD7 TRIAL

Michael J. Hoffmann, E. Nievergall, J. Dürig, 2022, HemaSphere.

Natural T-cell response against MHC class I epitopes of epithelial cell adhesion molecule, her-2/neu, and carcinoembryonic antigen in patients with colorectal cancer.

E. Thiel, H. Buhr, C. Scheibenbogen, 2000, Cancer research.